Table 3.
Ascitic fluid parameters in group II at the beginning and end of alternative therapy
| Variable | Meropenem subgroup | Levofloxacin subgroup | t | P value |
| (n = 11) | (n = 8) | |||
| At initiation of alternative therapy | ||||
| Glucose (mg/dL) | 100.45 ± 80.33 | 113.50 ± 9.58 | 0.390 | 0.702 |
| Protein (mg/dL) | 1850.00 ± 529.26 | 1360.83 ± 572.08 | 1.771 | 0.097 |
| LDH (IU/L) | 450 (108-1200) | 237 (120-831) | 2.223 | 0.042 |
| PMNLs/mm3 | 18 061 (957-23822) | 3540 (957-15222) | 3.622 | 0.000 |
| At end of therapy | ||||
| Glucose (mg/dL) | 102.81 ± 39.35 | 124.00 ± 29.17 | 1.150 | 0.268 |
| Protein (mg/dL) | 1660.00 ± 418.85 | 1163.33 ± 516.78 | 2.156 | 0.052 |
| PMNLs/mm3 | 316.01 ± 104.03 | 265.63 ± 69.61 | 1.056 | 0.307 |
Data are presented by mean ± SD or median (range). LDH: Lactate dehydrogenase; PMNLs: Polymorph nuclear leucocytes.